Sales & Marketing

Agreement includes option for PTC Therapeutics to sell up to all its retained royalties.

Extra capital brings overall funding to $59.5 million.

Initiative started as a response to climate change, company says.

Qlosi indicated for adult patients.

Etrasimod indicated for adult patients with moderate-to-severe diagnosis.

Drug supplier receives $3.45 billion in commitment in new financing.

Treatment indicated for patients with BRAF V600E-mutant metastatic form of disease.

Treatment previously received emergency use authorization by the FDA.

KYV-101 designed as a CD19 CAR T-cell therapy.

Site aims to advance regenerative medicines on a global scale.

Cosentyx is the first intravenous formulation interleukin-17A antagonist to focus on disease.

Developed by Bio-Thera Solutions, treatment is indicated for patients with three different types of arthritis.

Acquisition includes company’s inflammatory disease medicines.

Addition strengthens neuroscience pipeline, company says.

Lofaso discusses strategies that biotech companies can take once its time to make the big push.

Transaction made with intent to develop new drugs, company says.

Company expects treatment to be available across the country.

Separate entity allows company to concentrate on status as focused medicines company.

Collaboration to focus on ulcerative colitis and Crohn’s disease.

Acquired company focused on radioligand therapies for the treatment of cancer.

Currently in Phase III of clinical trials, Sanofi is expected to commercialize vaccine candidate.

Pombiliti + Opfolda indicated for adults who are not improving on current enzyme therapy.

Eye drop treatment indicated for pharmacologically induced mydriasis.

Deal comes amid first successful partnership.

Company expects to yield a significant number of new medicine launches from the acquisition.